ERAS in minimally invasive hepatectomy

Andrew K. Y. Fung, Charing C. N. Chong, and Paul B. S. Lai

Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong

Open hepatectomy is associated with significant post-operative morbidity and mortality profile. The use of minimally invasive approach for hepatectomy can reduce the post-operative complication profile and total length of hospital stay. Enhanced recovery after surgery (ERAS) programs involve evidence-based multimodal care pathways designed to achieve early recovery for patients undergoing major surgery. This review will discuss the published evidence, challenges and future directions for ERAS in minimally invasive hepatectomy. (Ann Hepatobiliary Pancreat Surg 2020;24:119-126)

Key Words: Enhanced recovery; Minimally invasive; Hepatectomy

INTRODUCTION

Traditionally, open hepatectomy is associated with significant post-operative morbidity (15-50%) and mortality (<5%).1-4 Post-operative complications will prolong hospital stay and patient suffering, and has a negative impact on long-term survival following hepatectomy for malignant conditions.5,6

Minimally invasive surgery (MIS) for hepatectomy is now an established technique, and has become a feasible procedure for liver resections.7-10 It is important to identify patient treatments that could further improve patients’ post-operative recovery and reduce complications after MIS hepatectomy.11

Enhanced recovery after surgery (ERAS) programs have been shown to reduce morbidity rates and total hospital stay in colorectal surgery.12 The aims of ERAS programs are the earlier return to normal homeostasis and functional activities by the implementation of therapies to reduce the physiological consequences of peri-operative surgical stress (Table 1).13 Pre-habilitation is the process of pre-operative patient optimisation with particular focus on physiotherapy, nutritional support and psychological preparation for major surgery.14,15

The evidence for using ERAS in MIS hepatectomy remains unclear. This review will focus on the role of ERAS within a MIS hepatectomy clinical pathway.

PUBLICATION SEARCH

A literature search of MEDLINE, PubMed, EMBASE was performed by the first author (AKYF) in August 2019 using the terminology of ERAS, enhanced recovery, liver resection, hepatectomy, fast track, enhanced rehabilitation, hepatic and hepatobiliary. The language of the literature was restricted to English.

ERAS PRINCIPLES AND OBJECTIVES

The pillars of ERAS include patient and healthcare provider engagement in shared decision-making, early enteral nutrition, goal-directed fluid therapy, avoidance of intra-abdominal drainage catheters and early post-operative mobilisation.16 In cancer surgery, rapid recovery after surgery is important to facilitate early initiation of adjuvant oncological therapies. ERAS programs can achieve this objective and potentially confer improvements in long-term cancer survival.17,18
ERAS AND OPEN HEPATECTOMY

There is increasing interest and published experience describing the application of ERAS principles to hepatectomy. van Dam et al. first reported the outcomes for ERAS in open liver resection. The study concluded that there was a two-day reduction in the median hospital stay ($p<0.001$) for patients who underwent the ERAS pathway.

ERAS programs in liver surgery can reduce complication rates by 30-60% compared to traditional post-operative care, and without an increase in re-admission rate. Several clinical trials have demonstrated the safety of ERAS combined with open hepatectomy.

Furthermore, mean duration of hospital stay and time to functional recovery can be reduced by 2.3 days and 2.5 days respectively. A meta-analysis on ERAS with open hepatectomy has also reported significant reductions in post-operative complications and hospital stay.

ERAS AND MIS HEPATECTOMY

There is increasing use of minimal invasive surgical (MIS) approach to hepatectomy. MIS hepatectomy has many advantages over traditional open hepatectomy, including reduced intra-operative blood loss, hospital stay and earlier return to functional activities, and has become standard practice for minor liver resections, especially left lateral sectionectomies.

The additional contribution of ERAS with MIS hepatectomy remains unclear. The combination of MIS hepatectomy with ERAS programs might have additional synergistic benefits for patients compared with MIS approach alone. Laparoscopic liver resection (LLR) combined with ERAS has been shown to reduce median hospital stay by two days compared to standard LLR alone.

ERAS AND MIS HEPATECTOMY: PUBLISHED LITERATURE

There are several published studies on ERAS and MIS hepatectomy (Tables 2, 3). Stoot et al. reported the outcomes of a pilot series of laparoscopic liver resections with and without ERAS. Thirteen patients underwent laparoscopic liver resections with ERAS and these patients had quicker return to functional recovery by two days ($p=0.04$). However, this finding was not transferred to a shorter hospital stay in the ERAS group, with similar median hospital stay between ERAS and non-ERAS groups (5 vs. 7 days, $p=0.3$).

Liang et al. reported eighty cases of laparoscopic liver resection within an ERAS program. Median post-operative hospital stay was 6.2 days compared to 9.9 days in the conventional group ($p<0.001$). These outcomes were similar to He et al. who reported on eight-six cases of laparoscopic hepatectomy with ERAS: there was a reduction in post-operative hospital stay of two days ($p<0.04$).

Sánchez-Pérez et al. did not find a statistically difference in the median post-operative hospital stay for laparoscopic liver resection with ERAS compared to standard care (2.5 vs. 3 days, $p=0.05$).

Ratti et al. compared the outcomes for MIS hepatectomy versus open hepatectomy within an ERAS program using propensity matching. Mortality was similar between the two groups, with lower morbidity in the MIS group (31.4 vs. 38.2%, $p=0.05$). Median length of hospital stay...
| Day before surgery                                                                 |
|----------------------------------------------------------------------------------|
| Pre-surgery education                                                            |
| Normal oral nutrition until midnight                                              |
| No pre-anaesthetic medication                                                    |

Table 2. Published randomised clinical trials on ERAS and MIS hepatectomy

| Stoot et al.\(^\text{36}\) 2009 | Sánchez-Pérez et al.\(^\text{39}\) 2012 | He et al.\(^\text{38}\) 2015 | Liang et al.\(^\text{37}\) 2016 | Wong-Lun-Hing et al.\(^\text{41}\) 2017 |
|----------------------------------|------------------------------------------|-----------------------------|---------------------------------|----------------------------------------|

| Day of surgery                   |
|----------------------------------|
| Pre-operative oral glucose       |
| administration 2 hours before    |
| operation                        |
| Mid-thoracic epidural anasthetist|
| and short-acting anaesthetics    |
| Avoidance of peri-operative fluid|
| overload                        |
| Non-opioid analgesia             |

| Post-operative D0                |
|----------------------------------|
| Restart oral intake of           |
| water/nutrition \(\text{ad libitum}\) |
| Oral intake 6-8 hours after      |
| operation                        |
| Mobilisation 6-8 hours after     |
| operation                        |
| Analgesia: intravenous            |
| metamizol every 8 hours and      |
| intravenous paracetamol every 8   |
| hours                            |

| Post-operative D1                |
|----------------------------------|
| Mobilisation four times a day     |
| Cessation of intravenous fluids   |
| Patient oral fluid intake >1500 mls |
| Normal diet                       |
| Continue portable epidural        |
| analgesia                         |
| 1 g panadol every 6 hours         |
| 1 g magnesium oxide twice daily   |

| Pre-operative oral glucose       |
| administration 2 hours before    |
| operation                        |
| No routine nasogastric tube or   |
| abdominal drainage               |
| Mid-thoracic epidural anasthetist|
| and short-acting anaesthetics    |
| Avoidance of peri-operative fluid|
| overload                        |
| No routine nasogastric or        |
| abdominal drainage               |

| Post-operative D0                |
|----------------------------------|
| Water intake 4 hours after       |
| operation                        |
| Mobilisation 12 hours after      |
| operation                        |
| Analgesia: oral                  |
| administration                    |
| Drain removal within              |
| 24-48 hours                       |
| Removal of urinary catheter      |
| Thoracic epidural                 |
| Daily review of discharge criteria|

| Post-operative D1                |
|----------------------------------|
| Mobilisation four times a day     |
| Cessation of intravenous fluids   |
| Patient oral fluid intake >1500 mls|
| Normal diet                       |
| Removal of urinary catheter      |
| Thoracic epidural                 |
| Daily review of discharge criteria|

| Oral nutritional supplements      |
| Mobilisation twice a day          |
| Removal of urinary catheter      |
| Reduce intravenous fluids        |

| Mobilisation four times a day     |
| Cessation of intravenous fluids   |
| Patient oral fluid intake >1500 mls|
| Normal diet                       |
| Removal of urinary catheter      |
| Continue portable epidural        |
| analgesia                         |
| 1 g panactamol every 6 hours      |
| Start laxatives                   |
Table 3. ERAS and MIS hepatectomy: clinical outcomes of the published literature

| Study                          | Number of patients | Type of liver resection                     | Primary outcome                          | Study result                                               |
|--------------------------------|--------------------|---------------------------------------------|------------------------------------------|-----------------------------------------------------------|
| Stoot et al.36 2009            | 13 ERAS            | Laparoscopic left lateral resection and minor resections | Total length of hospital stay (LOS) | Median LOS reduced in ERAS (5 vs. 7, p>0.05) |
| Case control study            | 13 conventional group |                                               |                                          |                                                           |
| Sánchez-Pérez et al.39 2012   | 26 ERAS            | Laparoscopic minor resections for benign and malignant disease | LOS                                    | Median LOS shorter in ERAS (3 vs. 2) Readmission rate (3.8% vs. 5.8%, p>0.04) Mortality 11.5% vs. 11.8% p>0.05 Mortality (nil in both groups) |
| Case control study            | 17 conventional group |                                               |                                          |                                                           |
| He et al.38 2015               | 48 ERAS            | Laparoscopic left lateral sectionectomy or wedge resection | Quality of life                          | Median LOS reduced in ERAS (6 vs. 10, p<0.04) QoL better in ERAS (p=0.04) |
| Randomised control trial       | 38 conventional group |                                               | Length of stay                          |                                                           |
| Liang et al.37 2016            | 80 ERAS            | Laparoscopic major and minor resections      | LOS                                      | Median LOS reduced in ERAS (6 vs. 10, p<0.001) reduced hospital costs (p<0.002) |
| Observational study            | 107 comparison group |                                               | Hospital expense                        |                                                           |
| Wong-Lun-Hing et al.41 2017    | 11 open left lateral sectionectomy | Laparoscopic versus open left lateral sectionectomy within ERAS program | Time to functional recovery       | RCT stopped due to slow patient recruitment |
| Randomised control trial       | 13 laparoscopic left lateral sectionectomy |                                               |                                          |                                                           |
and time to functional recovery was also shorter by two days in the MIS group ($p=0.04$). Finally, the ERAS protocol adherence rate was higher in the MIS group (83 vs. 77%), which could reflect the greater patient motivational levels in the ERAS group. The researchers also reported that the lower incidence of post-operative complications was directly related to higher rates of compliance to the ERAS pathway.

The ORANGE II (open versus laparoscopic left lateral hepatic sectionectomy within an enhanced recovery after surgery programme) randomised control trial aimed to analyse the outcomes of laparoscopic versus open left lateral sectionectomy within an ERAS setting. The primary outcome of this RCT was the time to functional recovery. One hundred and four patients were considered eligible for the study, but only twenty-four patients underwent the study interventions (eleven patients had open surgery and thirteen had laparoscopic surgery). There was no statistically significant difference in time to functional recovery between the open and laparoscopic ERAS groups (3 vs. 3 days, $p=0.28$), and also no difference between the ERAS and control (non-ERAS) groups. The trial also reported 40% patients stayed in hospital beyond the time of functional recovery, with logistical reasons accounting for 46%. Unfortunately, the clinical trial was stopped early due to poor patient recruitment and the additional role of ERAS with minor hepatectomy could not be determined.

Yang et al. performed a meta-analysis to evaluate the efficacy and safety of ERAS versus traditional care in laparoscopic hepatectomy. Eight studies were included in the meta-analysis, incorporating 580 patients. The ERAS group had faster return to first diet intake and flatus after surgery, reduced post-operative hospital stay and complication rates.

THE POTENTIAL PHYSIOLOGICAL BENEFITS AND CHALLENGES OF ERAS IN MIS HEPATECTOMY

Major fluid shifts can occur during hepatectomy, and patients with cirrhosis are especially sensitive to these fluid shifts. The maintenance of euvolaemia is critical for preservation of renal function and preventing ascites. One component of an ERAS program in liver surgery is goal-directed fluid therapy, which includes treatments such as low central venous pressure and reduced intra-operative fluid loading. This results in reduced operative blood loss, which is associated with reduced liver-specific surgical complications.

The presence of abdominal drains after hepatectomy can inhibit early post-operative mobilisation and increase wound discomfort. Additionally, nasogastric tube placement after liver resection has been also shown to increase post-operative surgical and pulmonary complications and patient discomfort. These two interventions are often avoided in ERAS programs for liver resection.

The challenges of ERAS programs in liver resection are multi-fold. For major liver resections, the risk of liver failure and bile leak is increased. The liver itself might be cirrhotic, which can predispose to both post-operative ascites and haemorrhage after open hepatectomy. Conversely, in cirrhotic patients undergoing MIS liver resections, there is preservation of porto-systemic shunts with no increase in portal pressure and subsequent reduction of post-operative ascites and bleeding. ERAS protocols might also be beneficial to cirrhotic patients by the omission of the overnight fasting and carbohydrate preloading can diminish the nutritional stress for this patient group.

Appropriate analgesia is an important aspect of an ERAS program. Epidural analgesia is a highly effective treatment after surgery. However, in liver surgery, patients can experience transient coagulopathy and epidurals can also prolong the prothrombin time after operation. Furthermore, epidural analgesia was associated with increased risk of blood transfusion without any reduction in the risk of post-operative complications or length of hospital stay. Presently, there are no optimal analgesia regimes for post-hepatectomy patients.

Nutrition remains a key component of the ERAS pathway to combat the catabolic phase and the increased septic risk after hepatectomy. Patients undergoing hepatectomy can experience wide fluctuations in the blood glucose levels, secondary to transient insulin resistance. Hyperglycaemia can negatively impact on post-operative recovery. Pre-operative carbohydrate loading as part of ERAS program can help ameliorate the effects of transient insulin resistance and the prolonged fasting state encountered as part of traditional pre-operative care. However, the published literature regarding carbohydrate loading before hepatectomy is lacking. Nonetheless, early feeding
and rapid progression to normal diet after hepatectomy is highly encouraged.34,62

Despite the evidence-based advantages of ERAS programs for major surgery, certain components of ERAS are more easily applied, as they are part of standard clinical routines, such as prophylactic antibiotic treatment and MIS approach. Other aspects of ERAS programs will require change from usual practice, including intra-operative fluid restrictive regimes, no intra-peritoneal drainage catheters and non-opioid based analgesia.65 In light of the challenges in achieving strict compliance to ERAS protocols, perhaps flexibility and a tailored approach might still result in satisfactory outcomes.64

Barriers to the initiation and establishment of ERAS programs include lack of clinical manpower and belief in the ERAS philosophies, lack of communication and collaboration between stakeholders, and an inherent resistance to change in clinical practice.65

FUTURE DIRECTIONS FOR ERAS IN MIS HEPATECTOMY

There remains significant heterogeneity and patient case-mix in the published meta-analyses regarding ERAS and hepatectomy.29 Unfortunately, future clinical studies comparing ERAS and traditional care pathways after liver resection might be considered unethical because ERAS protocols already contain evidence-based treatments that reduces surgical stress and post-operative catabolism.21,36

The ERAS literature has historically reported outcomes based on length of hospital stay (LOS) and post-operative complications.66 Some studies have highlighted the difference between readiness for discharge and actual LOS, as an issue that needs addressing in future ERAS programs.18 The difference in LOS might be more significant if these delays in hospital discharges can be avoided.36

The use of patient-centred outcome measures might provide a more accurate assessment of the success of an ERAS program.17 Consistent definitions of these outcome parameters will assist in future ERAS-orientated research, whilst systematic audit and appraisal will be important for improving compliance with these outcomes measures.31,63,65,67

Future research directions for ERAS and MIS hepatectomy might include the long-term data regarding the effects of ERAS on oncological outcomes. There is also increasing utilisation of the robotic platform for MIS hepatectomy, but presently, there is no proven advantage of robotic liver resection with ERAS.62

CONCLUSION

MIS hepatectomy has been shown to decrease hospital stay and post-operative complications, with faster return to baseline function when compared to open hepatectomy. ERAS programs in MIS hepatectomy can reduce the physiological stress of hepatectomy with the combination and synergistic benefits of small wounds, less post-operative pain and analgesia requirements. There will be less post-operative ileus as a consequence of restrictive intravenous fluid regime,68 early enteral nutrition,34 reduce use of analgesia that could affect gut motility,69 early mobilisation, avoidance of nasogastric tube50 and abdominal drainage.46-48 The challenge for hepatobiliary surgical teams is the integration of both MIS approach and ERAS to maximise the patient benefits.

CONFLICT OF INTEREST

No potential conflict of interest relevant to this article was reported.

ORCID

Andrew K. Y. Fung: https://orcid.org/0000-0002-7731-1638
Charing C. N. Chong: https://orcid.org/0000-0002-8425-8767
Paul B. S. Lai: https://orcid.org/0000-0002-9469-6728

AUTHOR CONTRIBUTIONS

Conceptualization: AKYF, CCNC, PBSL. Literature search: AKYF. Writing - original draft: AKYF. Writing - review & editing: AKYF, CCNC, PBSL.

REFERENCES

1. Benzoni E, Molaro R, Cedolini C, Favero A, Cojutti A, Lorenzin D, et al. Liver resection for HCC: analysis of causes and risk factors linked to postoperative complications. Hepatogastroenterology 2007;54:186-189.
2. Cescon M, Vetrone G, Grazi GL, Ramacciatto G, Ercolani G, Ravaioi M, et al. Trends in perioperative outcome after hepatic resection: analysis of 1500 consecutive unselected cases over 20 years. Ann Surg 2009;249:995-1002.

3. Ratti F, Cipriani F, Reineke R, Catena M, Comotti L, Beretta L, et al. Impact of ERAS approach and minimally-invasive tech- niques on outcome of patients undergoing liver surgery for hep- atocellular carcinoma. Dig Liver Dis 2016;48:1243-1248.

4. Dokmak S, Frériche FS, Borscheid R, Cauchy F, Farges O, Belghiti J. Liver resections in the 21st century: we are far from zero mortality. HPB (Oxford) 2013;15:908-915.

5. Mavros MN, de Jong M, Dogeas E, Hyder O, Pawlik TM. Impact of complications on long-term survival after resection of colorectal liver metastases. Br J Surg 2013;100:711-718.

6. Hughes MJ, Chong J, Harrison E, Wigmore S. Short-term out- comes of liver resection for malignant and benign disease in the age of ERAS. HPB (Oxford) 2016;18:177-182.

7. Coelsn MM, Wong-Lun-Hing EM, van Dam RM, van der Wilt AA, Lassen K, et al. A systematic review of outcomes in patients undergoing liver surgery in an enhanced recovery af- ter surgery pathways. HPB (Oxford) 2013;15:245-251.

8. Ni CY, Yang Y, Chang YQ, Cai H, Xu B, Yang F, et al. Fast-track surgery improves postoperative recovery in patients undergoing partial hepatectomy for primary liver cancer: a pro- spective randomized controlled trial. Eur J Surg Oncol 2013; 39:542-547.

9. Ni TG, Yang HT, Zhang H, Meng HP, Li B. Enhanced recovery after surgery programs in patients undergoing hepatectomy: a meta-analysis. World J Gastroenterol 2015;21:9209-9216.

10. Hughes MJ, McNally S, Wigmore SJ. Enhanced recovery fol- lowing liver surgery: a systematic review and meta-analysis. HPB (Oxford) 2014;16:699-706.

11. Nguyen KT, Gamblin TC, Geller DA. World review of laparo- scopic liver resection-2,804 patients. Ann Surg 2009;250:831- 841.

12. Kehlet H, Wilmore DW. Evidence-based surgical care and the evolution of fast-track surgery. Ann Surg 2008;248:189-198.

13. Manso M, Schmelz J, Aloia T. ERAS-Anticipated outcomes and realistic goals. J Surg Oncol 2017;116:570-577.

14. Bolshinsky V, Li MH, Ismail H, Burbury K, Riedel B, Heriot B. Multimodal prehabilitation programs as a bundle of care in gastrointestinal cancer surgery: a systematic review. Dis Colon Rectum 2018;61:124-138.

15. Le Roy B, Selvy M, Slim K. The concept of prehabilitation: what is the surgeon needs to know? J Visc Surg 2016;153:109-112.

16. Lillehoe AA, Aloia TA. Enhanced recovery after surgery: hepatobiliary. Surg Clin North Am 2018;98:1251-1264.

17. Day RW, Cleetland CS, Wang XS, Fielder S, Calhoun J, Conrad R, et al. Patient-reported outcomes accuracy measure the value of an enhanced recovery program in liver surgery. J Am Coll Surg 2015;221:1023-1030.e1-e2.

18. Morrison B, Kellihir L, Jones C. Enhanced recovery for liver resection-early recovery pathway for hepatocellular carcinoma: a systematic review. HPB (Oxford) 2018;7:217-220.

19. Kaibori M, Matsui K, Ishizaki M, Iida H, Yoshii K, Asano H, et al. Effects of implementing an "enhanced recovery after sur- gery" program on patients undergoing resection of hepatocellular carcinoma. Surg Today 2017;47:42-51.

20. Dasari BV, Rahman R, Khan S, Bennett D, Hodson J, Isaac J, et al. Safety and feasibility of an enhanced recovery pathway af- ter liver resection: prospective cohort study. HPB (Oxford) 2015;17:700-704.

21. van Dam RM, Hendry PO, Coelsn MM, Bernelmans MH, Lassen K, Revhaug A, et al. Initial experience with a multimodal enhanced recovery program in patients undergoing liver resection. Br J Surg 2008;95:969-975.

22. Jones C, Kellihir L, Dickinson M, Riga A, Worthington T, Scott MJ, et al. Randomized clinical trial on enhanced recovery versus standard care following open liver resection. Br J Surg 2013; 100:1015-1024.

23. Kapritsou M, Korkolis DP, Giannakopoulou M, Kaklanamos I, Konstantinou M, Katsoulas T, et al. Fast-track recovery program after major liver resection: a randomized prospective study. Gastroenterol Nurs 2018;41:104-110.

24. Ovaere S, Boscart I, Parmantier I, Stee lant PJ, Gabriel T, Allevaer t J, et al. The effectiveness of a clinical pathway in liver surgery: a case-control study. J Gastrointest Surg 2018;22:684-694.

25. Wu SJ, Xiong XZ, Lu J, Cheng Y, Lin YX, Zhou RX, et al. Fast-track programs for liver surgery: a meta-analysis. J Gastrointest Surg 2015;19:1640-1652.

26. Yang R, Tao W, Chen YY, Zhang BH, Tang JM, Zhong S, et al. Enhanced recovery after surgery programs versus traditional perioperative care in laparoscopic hepatocellular carcinoma: a meta-analysis. Int J Surg 2016;36(Pt A):274-282.

27. Song W, Wang K, Zhang RJ, Dai QX, Zou SB. The enhanced recovery after surgery (ERAS) program in liver surgery: a meta-analysis of randomized controlled trials. Springerplus 2016;5:207.

28. Li M, Zhang W, Jiang L, Yang J, Yan L. Fast track for open hepatocellular carcinoma: a systematic review and meta-analysis. Int J Surg 2016;36(Pt A):81-89.

29. Brustia R, Slim K, Scatton O. Enhanced recovery after liver surgery. J Visc Surg 2019;156:127-137.

30. Edwin B, Nordin A, Kazayran AM. Laparoscopic liver surgery: new frontiers. Scand J Surg 2011;100:54-65.

31. Lin NC, Nitta H, Wakabayashi G. Laparoscopic major hepa- toectomy: a systematic literature review and comparison of 3 techniques. Ann Surg 2013;257:205-213.

32. Twaij A, Pucher PH, Sodergren MH, Gall T, Darzi A, Jiao L.R. Laparoscopic vs open approach to resection of hepatocellular carcinoma in patients with known cirrhosis: systematic review and meta-analysis. World J Gastroenterol 2014;20:8274-8281.

33. Wakabayashi G, Cherqui D, Geller DA, Buell JF, Kaneko H, Han HS, et al. Recommendations for laparoscopic liver resection: a report from the second international consensus confer- ence held in Moriga. Ann Surg 2015;261:619-629.

34. Warner SG, Jutric Z, Nisimova L, Fong Y. Early recovery path- way for hepatocellular carcinoma: data-driven liver resection care and recovery. Hepatobiliary Surg Nutr 2017;6:297-311.

35. Alkhailhi E, Berber E. Laparoscopic liver resection for malignancy: a review of the literature. World J Gastroenterol 2014; 20:13599-13606.

36. Stoot JH, van Dam RM, Busch OR, van Hillegersberg R, De Boer M, Olde Damink SW, et al. The effect of a multimodal fast-track programme on outcomes in laparoscopic liver surgery: a multicentre pilot study. HPB (Oxford) 2009;11:140-144.

37. Liang X, Yang H, Wang H, Xu H, Yu H, Cai L, et al. Enhanced recovery program versus traditional care in laparoscopic hepato- cecomy. Medicine (Baltimore) 2016;95:e2835.

38. He F, Lin X, Xie F, Huang Y, Yuan R. The effect of enhanced recovery program for patients undergoing partial laparoscopic hepa- toectomy of liver cancer. Clin Transl Oncol 2015;17:694-701.

39. Sánchez-Pérez B, Aranda-Narváez JM, Suárez-Muñoz MA, Eladel-Delfresno M, Fernández-Aguilar JL, Pérez-Daga JA, et al. Fast-track program in laparoscopic liver surgery: theory or fact? World J Gastrointest Surg 2012;4:246-250.
M, et al. The clinical and biological impacts of the implementation of fast-track perioperative programs in complex liver resections: a propensity score-based analysis between the open and laparoscopic approaches. Surgery 2018;164:395-403.

41. Wong-Lun-Hing EM, van Dam RM, van Breukelen GJ, Tanis PJ, Ratti F, van Hillegersberg R, et al. Randomized clinical trial of open versus laparoscopic left lateral hepatic sectionectomy within an enhanced recovery after surgery programme (ORANGE II study). Br J Surg 2017;104:525-535.

42. Hammond JS, Guha IN, Beckhamming JJ, Lobo DN. Prediction, prevention and management of postresection liver failure. Br J Surg 2011;98:1188-1200.

43. Zimmitti G, Roses RE, Andreou A, Shindoh J, Curley SA, Aloia TA, et al. Greater complexity of liver surgery is not associated with an increased incidence of liver-related complications except for bile leak: an experience with 2,628 consecutive resections. J Gastrointest Surg 2013;17:57-64; discussion 64-65.

44. Poon RT, Fan ST, Lo CM, Liu CL, Lam CM, Yuen WK, et al. Improving perioperative outcome expands the role of hepatocarcinoma in management of benign and malignant hepatobiliary diseases: analysis of 1222 consecutive patients from a prospective database. Ann Surg 2004;240:698-708; discussion 708-710.

45. Jarnagin WR, Gonen M, Fong Y, DeMatteo RP, Ben-Porta L, Little S, et al. Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. Ann Surg 2002;236:397-406; discussion 406-407.

46. Fong Y, Brennan MF, Brown K, Hefferman N, Blumgart LH. Drainage is unnecessary after elective liver resection. Am J Surg 1996;171:158-162.

47. Petrovsky H, Demartines N, Rousson V, Clavien PA. Evidence-based value of prophylactic drainage in gastrointestinal surgery: a systematic review and meta-analyses. Ann Surg 2004;240:1074-1084; discussion 1084-1085.

48. Belghiti J, Kabbej M, Sauvanet A, Vilgrain V, Panis Y, Fekete F. Drainage after elective hepatic resection. A randomized trial. Ann Surg 1993;218:748-753.

49. Squires MH 3rd, Lad NL, Fisher SB, Koeoby DA, Weber SM, Brinkman A, et al. Value of primary operative drain placement after major hepatectomy: a multi-institutional analysis of 1,041 patients. J Am Coll Surg 2015;220:396-402.

50. Pessaux P, Regimbeau JM, Dondero F, Plass E, Mantz J, Belghiti J. Randomized clinical trial evaluating the need for routine nasogastric decompression after elective hepatic resection. Br J Surg 2007;94:297-309.

51. Pessaux P, van den Broek MA, Wu T, Olde Damink SW, Piardi T, Dejong CH, et al. Identification and validation of risk factors for postoperative infectious complications following hepatectomy. J Gastrointest Surg 2013;17:1907-1916.

52. Spetzler VN, Schepers M, Pimprins HO, Fischer L, Nashan B, Li J. The incidence and severity of posthepatic bile leaks is affected by surgical indications, preparative chemotherapy, and surgical procedures. Hepatobiliary Surg Nutr 2019;8:101-110.

53. Yin Z, Fan X, Ye H, Yin D, Wang J. Short- and long-term outcomes after laparoscopic and open hepatectomy for hepatocellular carcinoma: a global systematic review and meta-analysis. Ann Surg Oncol 2013;20:1203-1215.

54. Ho AM, Lee A, Karmakar MK, Samy W, Lai PB, Ho OA, et al. Hemostatic parameters after hepatectomy for cancer. Hepato-gastroenterology 2007;54:1494-1498.

55. Carli F. Physiologic considerations of Enhanced Recovery After Surgery (ERAS) programs: implications of the stress response. Can J Anaesth 2015;62:110-119.

56. Sakowska M, Docherty E, Linscott D, Connor S. A change in practice from epidural to intrathecal morphine analgesia for hepato-pancreato-biliary surgery. World J Surg 2009;33:1802-1808.

57. Page A, Rostad B, Staley CA, Levy JH, Park J, Goodman M, et al. Epidural analgesia in hepatic resection. J Am Coll Surg 2008;206:1184-1192.

58. Hughes M, McNally S, McKeown DW, Wignmore S. Effect of analgesic modality on outcome following open liver surgery: a systematic review of postoperative analgesia. Minerva Anestesiol 2015;81:541-556.

59. Sandström R, Drott C, Hyltander A, Arvidsson B, Scherstén T, Wickström I, et al. The effect of postoperative intravenous feeding (TPN) on outcome following major surgery evaluated in a randomized study. Ann Surg 1993;217:185-195.

60. Okabayashi T, Nishimori I, Yamashita K, Sugimoto T, Namikawa T, Maeda H, et al. Preoperative oral supplementation with carbohydrate and branched-chain amino acid-enriched nutrient improves insulin resistance in patients undergoing a hepatectomy: a randomized clinical trial using an artificial pancreas. Amino Acids 2010;38:901-907.

61. Sloop M, Nygren J, Myrenfors P, Thorell A, Ljungqvist O. Preoperative oral carbohydrate treatment attenuates immediate postoperative insulin resistance. Am J Physiol Endocrinol Metab 2001;280:E576-E583.

62. Melloul E, Hübner M, Scott M, Snowden C, Prentis J, Dejong CH, et al. Guidelines for perioperative care for liver surgery: Enhanced Recovery After Surgery (ERAS) Society recommendations. World J Surg 2016;40:2425-2440.

63. Abeles A, Kwasnicki RM, Darzi A. Enhanced recovery after surgery: current research insights and future direction. World J Gastrointest Surg 2017;9:37-45.

64. Lyon A, Payne CJ, Mackay GJ. Enhanced recovery programme in colorectal surgery: does one size fit all? World J Gastroenterol 2012;18:5661-5663.

65. Pearsall EA, Mebhi Z, Pitul KB, Aarts MA, McKenzie M, Leod RS, et al. A qualitative study to understand the barriers and enablers in implementing an enhanced recovery after surgery program. Ann Surg 2015;261:92-96.

66. Day RW, Fielder S, Calhoun J, Kehlet H, Gottumukkala V, Aloia TA. Incomplete reporting of enhanced recovery elements and its impact on achieving quality improvement. Br J Surg 2015;102:1594-1602.

67. Teixeira UF, Goldoni MB, Waechter FL, Sampaio JA, Mendes FF, Fonfes PRO. Enhanced recovery (ERAS) after liver surgery: comparative study in a Brazilian tertiary center. Arq Bras Cir Dig 2019;32:e1424.

68. Lobo DN, Bostock KA, Neal KR, Perkins AC, Rowlands BJ, Allison SP. Effect of salt and water balance on recovery of gastrointestinal function after elective colonic resection: a randomised controlled trial. Lancet 2002;359:1812-1818.

69. Kehlet H, Rung GW, Callesen T. Postoperative opioid analgesia: time for a reconsideration? J Clin Anesth 1996;8:441-445.